HealthQuill Nirsevimab
An advisory committee of the USFDA has given a “favourable benefit-risk profile” for Sanofi and AstraZeneca’s experimental drug nirsevimab, meant to treat lower respiratory tract disease in newborns, according to a statement from the Paris-based firm.
Drugs Health Pharma

FDA’s advisory panel backs Sanofi, AstraZeneca’s investigational drug for newborns

HQ Team June 9, 2023: An advisory committee of the USFDA has given a “favourable benefit-risk profile” for Sanofi and AstraZeneca’s experimental drug.

Read More
X